Assignee
MILTENYI BIOTEC BV & CO KG
DE·40 granted patents·65 pending applications·29 citations·filing 2015–2025
Top patents by PatentIndex Score
105 records- 0195US11531031B2Single use tubing set for making genetically modified donor cells for reinfusion into a patientMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted Dec 20, 2022·2 cites·12 claims
- 0295US11419935B2Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cellsMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Aug 23, 2022·5 cites·6 claims
- 0394US11883494B2Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered formMILTENYI BIOTEC BV & CO KG·Filed 2023·Granted Jan 30, 2024·2 cites·11 claims
- 0494US11499977B2Equipment and procedure for culturing, separating, and genetically modifying donor cells for reinfusion into a patientMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted Nov 15, 2022·1 cites·16 claims
- 0593US12246065B2Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigenMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Mar 11, 2025·1 cites·26 claims
- 0692US12498374B2Method for manufacturing a patient specific cell population using a multifunctional self-contained apparatus and tubing setMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Dec 16, 2025·0 cites·20 claims
- 0790US11639717B2Perestaltic pump and device for isolating cells from biological tissueMILTENYI BIOTEC BV & CO KG·Filed 2020·Granted May 2, 2023·2 cites·12 claims
- 0888US12318446B2Reducing side effects of immunotherapy using genetically modified hematopoietic cellsMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Jun 3, 2025·0 cites·19 claims
- 0987US12576148B2Engineered immune effector cells for cancer immunotherapy that are resistant to fratricide by virtue of having genetically modified surface antigensMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Mar 17, 2026·0 cites·22 claims
- 1086US11933787B2Devices and disposables for patient-specific cell therapy manufacturingMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted Mar 19, 2024·0 cites·16 claims
- 1185US11499976B2Device and procedure for producing a cellular pharmaceutical product enriched in genetically modified target cells at the bedside or in a surgical roomMILTENYI BIOTEC BV & CO KG·Filed 2020·Granted Nov 15, 2022·1 cites·21 claims
- 1284US10925944B2Cell population for use in treating cancerMILTENYI BIOTEC BV & CO KG·Filed 2015·Granted Feb 23, 2021·4 cites·7 claims
- 1382US12436151B2Conjugates having an enzymmatically releasable detection moiety and a barcode moietyMILTENYI BIOTEC BV & CO KG·Filed 2020·Granted Oct 7, 2025·1 cites·12 claims
- 1480US2024158812A1Systems and Methods for Point/Center-Of-Care ImmunotherapyMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 1576US12521434B2Hematopoietic cells with a modified CD antigen for reducing side effects of cancer immunotherapyMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Jan 13, 2026·0 cites·6 claims
- 1674USD1029292STest tubeMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted May 28, 2024·5 cites·1 claims
- 1771US12265211B2Microscope device with virtual objectiveMILTENYI BIOTEC BV & CO KG·Filed 2019·Granted Apr 1, 2025·1 cites·11 claims
- 1871US11366312B2Microscope device with enhanced contrast formed by light illumination transmitted in two different spectral rangesMILTENYI BIOTEC BV & CO KG·Filed 2019·Granted Jun 21, 2022·1 cites·11 claims
- 1971US2024248076A1Method and kit for characterizing dopaminergic progenitor cells obtained by differentiating pluripotent stem cellsMILTENYI BIOTEC BV & CO KG·Filed 2024·Application pending·0 cites
- 2071US2025216328A1White light scattering in optical biomolecule interaction analysisMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 2171US2025198998A1White light scattering in optical biomolecule interaction analysisMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 2270US2025085225A1Method for detection of cells by repetitive staining and destainingMILTENYI BIOTEC BV & CO KG·Filed 2024·Application pending·0 cites
- 2370US2025138019A1Method for selecting antigen recognizing moieties having specificity for a target structureMILTENYI BIOTEC BV & CO KG·Filed 2024·Application pending·0 cites
- 2469US12013522B2Microscope deviceMILTENYI BIOTEC BV & CO KG·Filed 2019·Granted Jun 18, 2024·1 cites·14 claims
- 2569US2025327068A1Method for Generation of a Nucleic Acid LibraryMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 2667US2024108723A1Chimeric Antigen Receptor Specific for Folate Receptor 1MILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 2766US2023407383A1Gene specific spatial rolling circle amplification and ngs sequencingMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 2865US12161705B2Chimeric antigen receptor specific for tumor cellsMILTENYI BIOTEC BV & CO KG·Filed 2020·Granted Dec 10, 2024·0 cites·2 claims
- 2965US2023383343A1Method Combining In Situ Target Amplification and Spatial Unique Molecular Identifier (SUMI) Identification Using RT-PCRMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3065US2023323438A1Method combining in situ target capture and spatial unique molecular identifier (sumi) identification with in vitro sequencing for high density spatial multiomicsMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3165US2026049301A1Barcoding of Nucleic Acids from Single CellsMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3264US2023175061A1Sequencing of dna by sequential addition/incorporation of 3` unprotected labeled nucleotidesMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 3364US2025137047A1Direct Synthesis of Oligonucleotides on Microtomed Tissue SlicesMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3463US2025360509A1Microfabricated droplet dispensor with immiscible fluid and genetic sequencerMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3562US2023348961A1Ex-situ sequencing of rca product generated in-situMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3662US2025154546A1Use of 3'-oxymethylene alkyl disulfide protected nucleotides for enzymatic dna and rna synthesisMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 3762US2023138285A1Bright and releasable labels for cell staining based on the conjugates with several sites of fluorophore releaseMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 3861US11612644B2Cell population for use in treating cancerMILTENYI BIOTEC BV & CO KG·Filed 2020·Granted Mar 28, 2023·0 cites·6 claims
- 3961US2024287580A1Unit-dna composition for spatial barcoding and sequencingMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 4061US2024094198A1Biological conjugates having an photogenerated acidic or basic releasable detection moiety on top of biological tissuesMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 4161US2021085769A1Chimeric antigen receptor specific for tumor cellsMILTENYI BIOTEC BV & CO KG·Filed 2020·Application pending·0 cites
- 4260USD1029247SPump for liquidsMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted May 28, 2024·2 cites·1 claims
- 4360US2025235477A1Method for targeted gene insertion into immune cellsMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 4460US2022411862A1Spatial sequencing with mictagMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 4560US2024110232A1Gene specific tissue information and sequencingMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 4659US12584824B2Method for extraction of target cells from 3D tissue by optical identificationMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Mar 24, 2026·0 cites·4 claims
- 4759US11767339B2Synthesis of reversible nucleotide terminators by in-situ thio-alkyl group transfer for use in DNA sequencing by synthesisMILTENYI BIOTEC BV & CO KG·Filed 2022·Granted Sep 26, 2023·0 cites·6 claims
- 4859US2023313274A1Photo-responsive oligonucleotidesMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 4959US2025164485A1Site-specific conjugation of single domain antibody fragments (vhh) using equilibrium transfer alkylation reagent (etac)MILTENYI BIOTEC BV & CO KG·Filed 2024·Application pending·0 cites
- 5058US12146188B2Method combining single cell gene expression mapping and targeted RNA or c-DNA sequencing using padlock oligonucleotides comprising a barcode regionMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Nov 19, 2024·0 cites·13 claims
Showing the top 50 of 105 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MILTENYI BIOTEC BV & CO KG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →